Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Mitsubishi Tanabe Pharma America to Present Healthcare Resource Utilization Data in RADICAVA ORS® (edaravone)-Treated ALS Patients at AMCP 2024 | ||
By: PR Newswire Association LLC. - 15 Apr 2024 | Back to overview list |
|
JERSEY CITY, N.J., April 15, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of one abstract in amyotrophic lateral sclerosis (ALS) at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting, being held in New Orleans, La., Apr. 15-18, 2024. "Understanding healthcare resource utilization is crucial for assessing RADICAVA ORS® (edaravone) cost-effectiveness, optimizing healthcare delivery, improving patient outcomes and guiding healthcare planning," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA. "Our data demonstrate not only the economic value of RADICAVA ORS, but also its potential to improve efficiency and reduce healthcare costs. These real-world results underscore our commitment to provide innovative treatments that make a meaningful difference in patient care and healthcare outcomes." MTPA's poster will be on display on Tuesday, Apr. 16 from 11 a.m.-6 p.m. and Wednesday, Apr. 17 from 9-11:30 a.m. in the Expo Hall. The presentation will include a preliminary analysis of demographics, characteristics and healthcare resource utilization data, as part of Optum's de-identified Clinformatics® Data Mart (CDM).
About RADICAVA® (edaravone) and RADICAVA ORS® (edaravone) Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc. (MTPA). The MTPC group companies began researching ALS in 2001 through an iterative clinical platform over a 13-year period. In 2015, edaravone was approved as RADICUT® for the treatment of ALS in Japan and South Korea. Marketing authorizations were subsequently granted in Canada (October 2018), Switzerland (January 2019), Indonesia (July 2020), Thailand (April 2021), Malaysia (December 2021) and Brazil (February 2024). Marketing authorization for RADICAVA® Oral Suspension was granted in Canada (November 2022) and Switzerland (May 2023), and RADICUT® Oral Suspension 2.1% was granted regulatory approval in Japan in December 2022. To date, in the U.S., RADICAVA and RADICAVA ORS have been used to treat over 14,600 people with ALS, with over 1.8-million days of therapy, and have been prescribed by more than 2,300 HCPs.2-4 IMPORTANT SAFETY INFORMATION Hypersensitivity Reactions Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA or RADICAVA ORS, treat per standard of care, and monitor until the condition resolves. Sulfite Allergic Reactions Adverse Reactions Pregnancy To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. INDICATION For more information, including full Prescribing Information, please visit www.RADICAVA.com. About Mitsubishi Tanabe Pharma America, Inc. About Mitsubishi Tanabe Pharma Corporation Media inquiries: 1 RADICAVA and RADICAVA ORS Prescribing Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; 2022. View original content to download multimedia:https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-to-present-healthcare-resource-utilization-data-in-radicava-ors-edaravone-treated-als-patients-at-amcp-2024-302115041.html SOURCE Mitsubishi Tanabe Pharma America |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |